N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Acinetobacter Baumannii-calcoaceticus Complex · Hospital-acquired Bacterial Pneumonia · Ventilator-associated Bacterial Pneumonia
Primary: Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population — 12; 20 Participants
Phase 3 N=333 Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
Complicated Urinary Tract Infection · Complicated Intra-abdominal Infection
Primary: Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set — 6; 8; 129; 132 Participant
Phase 4 N=60 Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
Urinary Tract Infection · Acute Pyelonephritis · Hospital Acquired Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit - Microbiologically Modified Intent-to-Treat (mMITT) Analysis Set — 59.3; 25.9 Percentage of…
N/A N=339,902 Active Bathing to Eliminate Infection (ABATE Infection) Trial
Healthcare Associated Infections · Methicillin Resistant Staphylococcus Aureus · Multi Drug Resistant Organisms
Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
N/A N=530 Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Phase 3 N=464 Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Pneumonia · Blood Stream Infection
Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21
N/A N=100 Modified Reporting of Positive Urine Cultures Collected From Long Term Care
Urinary Tract Infections · Asymptomatic Bacteriuria
Primary: Proportion of Asymptomatic Bacteriuria Treated With Antibiotics and Urinary Tract Infection Treated With Antibiotics — 31; 25 Participants
Phase 3 N=69 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Bloodstream Infections (BSI) Due to CRE · Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE · Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE
Primary: Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat…
N/A N=500 Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
Gram-negative Bacteremia
Primary: Hours to First Antibiotic Modification — 24.7; 19.0 hours — p=0.013
Phase 3 N=450 Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Primary: Day 14 All-cause Mortality Rate — 3.0; 2.7 percentage of participants
Phase 1 N=10 Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
Cystic Fibrosis · Burkholderia Cepacia Infection
Primary: The Change in Sputum Density of BCC in Colony Forming Units (CFUs)/ml From Day 0 to Day 28 of TIP Treatment. — -1.4 CFU/ml log10
N/A N=418 Targeted Infection Control in Long-term Care
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Phase 2 N=143 Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia
Pneumonia, Bacterial
Primary: Change From Baseline in Clinical Pulmonary Infection Score (CPIS) For Each Patient, Value Obtained From a Daily Assessment Over the 10 Day Study Period Was Compared to…
N/A N=271 Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Sepsis · Procalcitonin · Antimicrobial Stewardship
Primary: Days of Antibiotic Therapy in the First 14 Days Following Randomization — 7.6; 6.6 days
N/A N=203 Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
N/A N=189 Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Gram Negative Infections
Primary: Number of Participants With Clinical Symptom Improvement at Day 3 — 82; 21 Participants
Phase 3 N=422 A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.
Complicated Intra-abdominal Infection · Hosptial Acquired Pneumonia · Ventilator Associated Pneumonia
Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set — 68.4; 65.7 Percentage of participants
Phase 3 N=50 Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
Bacterial Infections
Primary: Percentage of Participants With Favorable Overall Response (FOR) — 71.4; 70.0 Percentage of Participants
Phase 1 N=10 A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
Pharmacokinetics of Avycaz in ICU Patients
Primary: Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients — 34 Liter
Phase 3 N=75 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Urinary Tract Infection Complicated · Acute Pyelonephritis · Hospital Acquired Bacterial Pneumonia
Primary: Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success…
Phase 4 N=152 Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
Primary: Bacterial Clearance Rate of Sputum — 38; 16 Participants
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
N/A N=463 A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants
N/A N=20 Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
Bacterial Infections
Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL